Posted by Michael Wonder on 04 Nov 2023
Medicare is urged to consider Amgen patent manoeuvres when negotiating the price for a drug
31 October 2023 - As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group argues the agency should factor in controversial patent manoeuvres for one drug that will have cost the program nearly $2 billion in additional spending by 2026.
At issue is the Enbrel medication sold by Amgen for treating rheumatoid arthritis and other ailments.
